IPO Timeline Raw facts
Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 恒瑞医药 |
|---|---|
| Other Market Stock Code | 600276 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Hengrui Pharma |
|---|---|
| Stock Code | 01276 |
| Company Full Name | To be extracted |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家根植中國、全球領先的創新型制藥企業,聚焦腫瘤、代謝和心血管疾病、免疫和呼吸系統疾病以及神經科學等領域進行新藥研發,是國內最具創新能力的制藥龍頭企業之一。 |
| Listing Date | 2025-05-23 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省連云港市經濟技術開發區昆侖山路7號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.hengrui.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 44.05 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 41.8% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 2,126,372,790 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 8,810 |
| 2 lots | 400 | HK$ 17,620 |
| 3 lots | 600 | HK$ 26,430 |
| 4 lots | 800 | HK$ 35,240 |
| 5 lots | 1,000 | HK$ 44,050 |
| 6 lots | 1,200 | HK$ 52,860 |
| 7 lots | 1,400 | HK$ 61,670 |
| 8 lots | 1,600 | HK$ 70,480 |
| 9 lots | 1,800 | HK$ 79,290 |
| 10 lots | 2,000 | HK$ 88,100 |
| 15 lots | 3,000 | HK$ 132,150 |
| 20 lots | 4,000 | HK$ 176,200 |
| 25 lots | 5,000 | HK$ 220,250 |
| 30 lots | 6,000 | HK$ 264,300 |
| 35 lots | 7,000 | HK$ 308,350 |
| 40 lots | 8,000 | HK$ 352,400 |
| 45 lots | 9,000 | HK$ 396,450 |
| 50 lots | 10,000 | HK$ 440,500 |
| 100 lots | 20,000 | HK$ 881,000 |
| 150 lots | 30,000 | HK$ 1,321,500 |
| 200 lots | 40,000 | HK$ 1,762,000 |
| 250 lots | 50,000 | HK$ 2,202,500 |
| 300 lots | 60,000 | HK$ 2,643,000 |
| 350 lots | 70,000 | HK$ 3,083,500 |
| 400 lots | 80,000 | HK$ 3,524,000 |
| 450 lots | 90,000 | HK$ 3,964,500 |
| 500 lots | 100,000 | HK$ 4,405,000 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,000 lots | 200,000 | HK$ 8,810,000 |
| 1,500 lots | 300,000 | HK$ 13,215,000 |
| 2,000 lots | 400,000 | HK$ 17,620,000 |
| 2,500 lots | 500,000 | HK$ 22,025,000 |
| 3,000 lots | 600,000 | HK$ 26,430,000 |
| 3,500 lots | 700,000 | HK$ 30,835,000 |
| 4,000 lots | 800,000 | HK$ 35,240,000 |
| 4,500 lots | 900,000 | HK$ 39,645,000 |
| 5,000 lots | 1,000,000 | HK$ 44,050,000 |
| 10,000 lots | 2,000,000 | HK$ 88,100,000 |
| 15,000 lots | 3,000,000 | HK$ 132,150,000 |
| 20,000 lots | 4,000,000 | HK$ 176,200,000 |
| 25,000 lots | 5,000,000 | HK$ 220,250,000 |
| 30,871 lots | 6,174,200 | HK$ 271,973,510 |
Stock Connect Inclusion Analysis
| HK Market Cap | --- |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 55.15 |
|---|---|
| First Day Open | HK$ 57.0 |
| First Day Change | 25.20% |
| First Day Volume | 82663800.0 |
| First Day Turnover | 4733500000.0 |
| Use of Proceeds | 1、約75%或7,093.4百萬港元將用于研發計劃;
2、約15%或1,418.7百萬港元將用于在中國和海外市場建設新的生產和研發設施;
3、約10%或945.8百萬港元將用作營運資金及其他一般企業用途。 |
Underwriting Syndicate
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Cordial Solar Limited | 309,997,470 HKD | — | 3.13% | — | 6 months | 2025-11-23 |
| 2 | GIC Private Limited | 2,076,992,740 HKD | — | 21.00% | — | 6 months | 2025-11-23 |
| 3 | Hillhouse Funds | 309,997,470 HKD | — | 3.13% | — | 6 months | 2025-11-23 |
| 4 | Invesco Advisers, Inc | 581,248,560 HKD | — | 5.88% | — | 6 months | 2025-11-23 |
| 5 | Millennium Capital Management (Singapore) Pte. Ltd. | 232,495,900 HKD | — | 2.35% | — | 6 months | 2025-11-23 |
| 6 | Oaktree Funds | 154,994,330 HKD | — | 1.57% | — | 6 months | 2025-11-23 |
| 7 | UBS Asset Management (Singapore) Ltd. | 464,991,800 HKD | — | 4.70% | — | 6 months | 2025-11-23 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 孫飄揚 | — |
| Company Secretary | 劉笑含,梁頴嫻 | — |
Major Shareholders
| Major Shareholders & Holdings | 江蘇恒瑞醫藥集團有限公司(23.3%),西藏達遠企業管理有限公司(14.4%) |
|---|
Market Sentiment
The IPO was heavily oversubscribed at 454.85x, reflecting intense market demand. Despite this, the hit rate of 45.34% indicates a relatively high allocation rate, likely due to a large applicant pool of 203,874 individuals. The offer price was set at HK$44.05, though no range data is available for comparison. This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.
Tier Analysis
The expected allocation sharply differs between tiers: investors in the last A-tier (甲尾) receive only 0.5751 lots on average, while the first B-tier (乙头) secures exactly 1.0 lot, a 74% advantage. This wide gap suggests that applying at the B-head threshold was significantly more efficient in obtaining a full lot allocation, even after accounting for the higher capital requirement. Broker fee structures and actual costs may vary, and this analysis does not constitute investment advice. This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.
Demographics
Mainland Chinese investors dominated participation at 71.2%, typical for popular Hong Kong IPOs. The applicant base skews male (61.9%) and has an average age of 41.2, indicating a mature, likely experienced investor profile. Regional breakdowns beyond mainland vs. Hong Kong were not provided, but high mainland interest often correlates with strong sentiment. Data may contain errors or omissions from source documents — verify against official HKEX filings. This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.




